Clinical Trials Browser

Active not recruiting × Interventional × lorlatinib × Clear all

NCT05297890 2026-05-19

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

NCT06282874 2026-04-09

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Phase 4 Active not recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT05740943 2026-01-20

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05144997 2025-12-17

Lorlatinib Continuation Study

Phase 4 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03052608 2025-11-25

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Phase 3 Active not recruiting

296 enrolled 28 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04621188 2025-09-24

Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

Phase 2 Active not recruiting

Non Small Cell Lung Cancer Metastatic

NCT04127110 2024-11-05

ALKALINE

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung